Benzinga · Jul 30, 2026
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study
IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting completion by Q2 2029.
IM
NASDAQ · IMNN
Imunon, Inc.
Healthcare · Biotechnology
$1.61
Down-$0.03 (-1.86%)
Updated Aug 13, 2026, 11:08 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 10.46M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $1.47 – $3.30
- Volume
- 27.09K
- Avg. volume
- 90.7K
Price performance
IMNN price history
1M range · 21 trading sessions · Daily adjusted prices
IMNN closed at $1.61 after 21 trading sessions, down 16.58% for the selected period.
- Last close
- $1.61
- Period change
- -16.58%
- Period low
- $1.51
- Period high
- $1.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.63 | $1.64 | $1.59 | $1.61 | 27.09K |
| Aug 11, 2026 | $1.61 | $1.67 | $1.5641 | $1.61 | 54.94K |
| Aug 10, 2026 | $1.63 | $1.68 | $1.58 | $1.63 | 39.34K |
| Aug 7, 2026 | $1.64 | $1.64 | $1.58 | $1.61 | 21.71K |
| Aug 6, 2026 | $1.6769 | $1.6769 | $1.55 | $1.58 | 38.49K |
| Aug 5, 2026 | $1.6072 | $1.65 | $1.55 | $1.59 | 45.28K |
| Aug 4, 2026 | $1.58 | $1.72 | $1.57 | $1.67 | 98.57K |
| Aug 3, 2026 | $1.57 | $1.63 | $1.55 | $1.58 | 36.48K |
| Jul 31, 2026 | $1.58 | $1.61 | $1.57 | $1.59 | 50.18K |
| Jul 30, 2026 | $1.66 | $1.72 | $1.52 | $1.60 | 665.96K |
| Jul 29, 2026 | $1.50 | $1.5411 | $1.50 | $1.54 | 40.01K |
| Jul 28, 2026 | $1.52 | $1.5756 | $1.47 | $1.53 | 31.74K |
| Jul 27, 2026 | $1.52 | $1.5885 | $1.48 | $1.53 | 79.17K |
| Jul 24, 2026 | $1.63 | $1.64 | $1.51 | $1.51 | 91.96K |
| Jul 23, 2026 | $1.60 | $1.68 | $1.5319 | $1.66 | 156.37K |
| Jul 22, 2026 | $1.70 | $1.70 | $1.545 | $1.59 | 179.43K |
| Jul 21, 2026 | $1.81 | $2.00 | $1.59 | $1.67 | 3.55M |
| Jul 20, 2026 | $1.76 | $1.80 | $1.75 | $1.77 | 15.33K |
| Jul 17, 2026 | $1.88 | $1.88 | $1.79 | $1.83 | 30.54K |
| Jul 16, 2026 | $1.97 | $2.01 | $1.86 | $1.89 | 38.63K |
| Jul 15, 2026 | $1.98 | $2.03 | $1.9297 | $1.93 | 19.75K |
Latest IMNN news
The latest Smart Investors Daily articles mentioning IMNN.
Stock researchCompany · Overview
IMNN research
Overview
Company profile and research snapshot.
Company profile
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 17, 2026 | Maxim Group | Buy | — |
| May 19, 2025 | D. Boral Capital | Hold | — |
| May 13, 2025 | D. Boral Capital | Buy | — |
| May 7, 2025 | D. Boral Capital | Buy | — |
| Mar 26, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Jul 23, 2026
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism First-of-its-kind meeting spotlights IMNN-001 as one of the novel technologies shaping the future of cancer drug discovery and development LAWRENCEVILLE, N.J., July 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that new data on IMNN
Benzinga · Jul 23, 2026
IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And Development
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanismFirst-of-its-kind meeting spotlights IMNN-001 as one
Yahoo · Jul 21, 2026
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance with IMNN-001 vs. controlHighly favorable safety and tolerability profile Study, conducted in partnership with Break Through Cancer, provides new translational data and further support for IMNN-001's unique mechanism of remodeling the tumor immune microenvironment LAWRENCEVILLE, N.J., July 21, 2026
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
